INTEGRA LIFESCIENCES HOLDINGS CORP — Form 8-K
Filed September 8, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 62/100
What the filing says
Integra LifeSciences Holdings Corp (market cap ~$925M) presented investor update on FDA remediation progress. LTM Q2 2026 revenue $1,648M (+1.6% YoY), Adjusted EBITDA $337M (+11.8% YoY, 20.5% margin). New Braintree, MA manufacturing facility operational Q2 2026; SurgiMend relaunch on track Q4 2026. All FDA warning letter commitments targeted for completion in 2026. LTM FCF $26M (vs. -$31M in 2025). Net leverage improved to 4.1x from 4.5x (target 2.5–3.5x).
Why this rating
Meaningful operational inflection after 3-year remediation. Braintree delivery validates execution; product relaunch and cost normalization support margin/FCF recovery, but revenue growth remains flat. Significant relative to $925M market cap.
See more from September 8, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.